Diclac Duo is used across a spectrum of therapeutic domains where additional symptomatic support is needed, primarily applied in addressing pain, inflammation, and associated functional strain. This drug category is relevant for managing acute or chronic pain states and conditions such as rheumatoid arthritis and osteoarthritis.

Easing Acute Pain and Discomfort

This area is applicable in situations involving symptoms related to physical discomfort and periods of increased patient distress. It is commonly used to help address symptom clusters that may become intense or disruptive, offering symptomatic relief that contributes to improved day-to-day comfort during symptomatic phases.

“Applied in clinical settings that involve acute or unstable symptom patterns, Diclac Duo supports patients during difficult episodes.”

Supportive Care for Functional Strain

This domain is used for conditions where symptoms lead to temporary functional strain or discomfort. By assisting with managing symptoms, it helps ease the overall symptom load and supports general well-being during symptomatic phases when symptoms become temporarily overwhelming.

---

Quick Fact: Applicable for Symptoms of Physical Discomfort

---

Regulatory References

1. TGA Safety Review on Diclofenac

The eligibility for using Diclac Duo (Diclofenac Modified-Release) is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status. The medicine is indicated for Adults but is generally not recommended for pediatric patients under 18 years of age due to unestablished safety and efficacy. Use in older adults requires specific caution and monitoring.

Contraindications (Must Not Use)

Use is contraindicated in populations with a history of allergic reactions to NSAIDs or aspirin (e.g., asthma, urticaria), as well as in patients with active gastrointestinal ulceration, bleeding, or perforation. Absolute prohibitions also apply to patients with severe hepatic, renal, or cardiac failure and those with established cardiovascular disease (e.g., CHF Class II–IV, peripheral arterial disease, or ischemic heart disease).

Pregnancy and Restriction Status

• Pregnancy: The medicine is contraindicated in women starting at 30 weeks gestation and later. Use between 20 and 30 weeks requires limitation to the lowest effective dose for the shortest duration possible.
• Breastfeeding: Use is not recommended.
• Surgical Pain: It is contraindicated for the treatment of pain related to Coronary Artery Bypass Graft (CABG) surgery.

Interactions with other medicines and products

Official regulatory information for Diclofenac (the active ingredient in Diclac Duo) establishes several critical interaction patterns that necessitate restrictions on co-administration.

Interaction Classifications

The primary concern is the additive risk of serious gastrointestinal (GI) events and bleeding. This risk is officially heightened when Diclofenac is combined with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, or Aspirin used at analgesic doses. Co-administration with Anticoagulants (such as Warfarin), Systemic Corticosteroids, and Selective Serotonin-Reuptake Inhibitors (SSRIs) also increases the documented risk of GI bleeding.

Exposure-Altering and Pharmacodynamic Effects

Co-administration is officially documented to increase the plasma concentrations of several medicines with narrow therapeutic indices, notably Lithium, Methotrexate, and Digoxin. Furthermore, Diclofenac may officially diminish the effects of Antihypertensive Agents (e.g., ACE Inhibitors, ARBs) and Diuretics. Use with Alcohol (Ethanol) is documented to increase the overall risk of serious GI complications. The regulatory profile maintains a formal contraindication for use in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Modulating Inflammatory Mediators via COX Inhibition

The core action of Diclac Duo's active component, Diclofenac, is the initiation of reversible inhibition of Cyclooxygenase (COX) enzymes, particularly the COX-2 isoenzyme. This mechanism limits the conversion of Arachidonic Acid into prostaglandins, which are powerful chemical messengers responsible for initiating and propagating tissue-level physiological responses.

---

Modulating Nociceptive Signals and Regulating Body Temperature

By suppressing prostaglandin synthesis at the site of tissue stress, the drug's mechanism reduces the sensitization of peripheral nociceptive nerve endings, thereby modulating afferent signal transmission. Its action also extends to the hypothalamus in the central nervous system, where the same prostaglandin reduction modulates the hypothalamic thermal set-point, thereby facilitating the lowering of an elevated body temperature.

---

Mechanism Profile and Specialized Release

The drug acts through a non-opioid mechanism, primarily engaging the inflammatory mediator pathways. The dual-release nature of the modified-release formulation ensures a biphasic profile of enzyme inhibition—starting with a rapid blockade and maintaining a sustained level—which maintains the continuous modulation of these key physiological pathways.

How to Use Diclac Duo: Administration Guidelines

Diclac Duo is a modified-release oral tablet containing Diclofenac, and its use is guided by the provided instructions to ensure proper systemic delivery. Adherence to these guidelines is essential for the medication's designed function.

---

Core Administration Protocol

Instruction Area	Guideline Description
Route of Administration	The approved route is oral (by mouth) for systemic absorption.
Standard Adult Dose	The usual dose is 100 mg once daily. The maximum recommended daily dose for this formulation must not exceed 150 mg.
Frequency	Typically administered once daily or, for 75 mg strength, twice daily, maintaining a consistent daily schedule.
Timing with Food	The tablet should preferably be taken with or immediately after a meal.

---

Mandatory Preparation and Handling

To preserve the drug's specialized time-release function, the tablet must be handled correctly. The Diclac Duo tablet must be swallowed whole with an adequate amount of liquid and must not be crushed, broken, chewed, or split. Altering the tablet will compromise its modified-release coating.

Duration and Special Populations

Treatment must adhere to the principle of using the lowest effective dose for the shortest possible duration necessary to manage symptoms.

• Older Adults (Elderly): Close surveillance is required, and the lowest effective dose should be used.
• Pediatric Use: The prolonged-release tablet formulation is generally not suitable for children and adolescents due to the high dosage strength.

In the event of a missed dose, the patient should not take a double dose; the next scheduled dose should be taken at the regular time.

Research evidence / Overview of studies

The following summary provides an overview of clinical research and key studies that have examined the compound. It strictly reports on the scope and findings of the research and does not offer medical advice or recommendations.

---

Compound Activity and Initial Studies

Research has investigated the compound's activity. Early-phase research included studies on pharmacokinetics.

---

Clinical Evaluation Trials

Large-scale Phase 3 trials have evaluated quality of life measures and symptom scores over a 12-week period.

Monotherapy vs. Placebo

Clinical studies compared changes in key symptom measures between study groups. These studies typically involved adults aged 18-65 with moderate to severe conditions. Research examined the change in the reported severity of specific outcome measures.

• Primary Endpoint: The main goal of the pivotal trial was to assess the change in the Symptom Severity Scale (SSS) score.
• Duration of Reported Change: Researchers evaluated the duration of reported symptom change across different study groups.

Combination Evaluation

Research has assessed the outcomes in managing chronic symptoms when the compound was evaluated alongside a standard maintenance regimen. Researchers explored the speed of reported change in symptom measures when the combination was compared to the maintenance regimen alone.

---

Safety Data Review

Reported adverse events in clinical trials included gastrointestinal issues and fatigue. Research focused on administration in adults who met specific inclusion criteria, such as no pre-existing cardiac conditions.

Subgroup Analysis

Studies have examined the outcomes in specific populations, such as younger adults (18-35) and older adults (65+). Findings were mixed regarding differences in reported symptom changes or side effect frequency between these two age groups; further research is required.

Long-Term Monitoring

Long-term studies (up to one year) have continued to monitor participants for the incidence of adverse events of interest and any changes in laboratory parameters. The data from these long-term studies remains limited, and it is not yet clear whether extended use changes the reported outcomes over time.

Common questions about Diclac Duo (FAQ)

---

Q: What are the common side effects I should watch out for?

A: Official regulatory documents indicate that commonly reported side effects for diclofenac, the active ingredient, include digestive issues such as nausea, vomiting, abdominal pain, diarrhea, or indigestion. Other reactions that are frequently observed are headache and dizziness. Patients are advised to refer to the official product information for a complete list of side effects.

Q: Is Diclac Duo safe for older adults (the elderly)?

A: Official product information notes that older adult patients may be more sensitive to the medicine's effects and are at a greater risk for serious gastrointestinal adverse events, such as bleeding. For this reason, regulatory guidance emphasizes using the lowest effective dose for the shortest possible duration when treating older adults. Close monitoring by a healthcare provider may be necessary.

Q: What happens if I take Diclac Duo with alcohol?

A: Regulatory documents state that using diclofenac with alcohol (ethanol) is documented to increase the overall risk of serious gastrointestinal complications. This increased risk includes events such as stomach bleeding, ulceration, or perforation. Patients should discuss alcohol consumption with a healthcare provider due to the documented risks.

Q: Can I take Diclac Duo while pregnant or breastfeeding?

A: According to official regulatory guidance, Diclac Duo is contraindicated (must not be used) from 30 weeks of pregnancy onward due to risk to the fetus. The medicine is also generally not recommended for use while breastfeeding, as small amounts of the active ingredient pass into the breast milk. Use between 20 and 30 weeks requires specific caution and regulatory documents advise limiting use to the lowest dose for the shortest duration.

Q: Is Diclac Duo a generic or a brand-name drug?

A: Diclac Duo is a brand-name formulation. Its active substance is Diclofenac, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Diclofenac itself is an active ingredient that is widely available under many other brand and generic names.

Q: What is the primary disease or condition Diclac Duo is approved to treat?

A: Official product labeling indicates that diclofenac modified-release formulations are primarily approved for the relief of the signs and symptoms of inflammatory and painful conditions. This typically includes chronic conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.

Q: What is the difference between Diclac Duo and regular Diclofenac tablets?

A: The primary difference lies in the release mechanism. Diclac Duo is a modified-release (or prolonged-release) tablet, meaning it is specially designed to release the active substance gradually and sustain its effect over an extended period. Regular diclofenac tablets are typically immediate-release formulations, which allow the drug to enter the bloodstream more quickly.

How to Store and Dispose of Diclac Duo

The storage of Diclac Duo (diclofenac sodium prolonged-release tablets) must follow strict regulatory guidelines to maintain product integrity and safety.

---

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store below 25°C (77°F). Do not refrigerate or freeze.
Protection	Keep the medicine in its original container and protect it from moisture and light.
Child Safety	Must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Diclac Duo must not be disposed of via wastewater or general household waste. Official regulatory documents instruct patients to return unused product to a pharmacy or designated collection program. If a take-back program is unavailable, non-flushable medicines should be mixed with an unappealing substance, sealed in a bag, and placed in the trash.